Iopamidol as an oral contrast media for computed tomography: a taste comparison to iohexol, diatrizoate sodium, and barium sulfate

Rogers, Douglas; Sheth, Chandni; Eisenmenger, Laura; Mignogna, Eugene; Winter, Thomas C.

doi:10.1007/s00261-017-1226-0

Cited by 10 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Palatability is a major reason for nonacceptance of OCM and remains a core issue of noncompliance with the drink protocol. Similar to participants in prior studies, participants in our cohort also demonstrated a strong preference toward thin, neutral-tasting ICM over flavored BCM with lesser adverse effects and no difference in experience with the two ICM concentrations (21)(22)(23). Of the approved OCM solutions, BCM suspension provides a relatively easier workflow because it is available in ready-to-dispense packaging, but its concentration cannot be altered.…”

Section: Discussionsupporting

confidence: 76%

“…While barium-based OCMs (BCMs) are the most readily available preparations, these suspensions cannot be optimized by dilution because of flocculation (20). In contrast, iohexol, an iodinated OCM (ICM), another agent approved by the U.S. Food and Drug Administration, can be diluted to customize the attenuation of intestinal contrast (21)(22)(23). Furthermore, patients with cancer, who undergo multiple CT examinations, have chemosensory alterations that impact oral intake; therefore, palatable OCM solutions are important to improve protocol compliance and obtain optimal luminal attenuation (24).…”

Section: Key Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial

et al. 2019

View full text Add to dashboard Cite

ositive oral contrast medium (OCM) is routinely used in the imaging of patients undergoing oncologic treatment and in patients after surgery for detecting extraluminal lesions and collections, defining anatomy, and assessing bowel integrity, especially in patients with insufficient visceral fat (1-3). Current oncology and American College of Radiology guidelines advocate the use of positive OCM, despite its influence on workflow (4,5). The latest-generation CT scanners provided by major manufacturers are equipped with two increasingly adopted techniques-namely, automated tube voltage (in kilovolt peaks) selection (ATVS) and dual-energy CT. This is because of well-established applications of these techniques that provide diagnostic image quality with high image contrast and enable material characterization (6-9). Both low-kVp and low-keV virtual monochromatic images (low-keV image reconstructions from dual-energy CT) augment the attenuation of iodine by two-to fourfold, and this property is being leveraged to reduce the dose of intravenous contrast medium (10-12). To achieve the average accepted enteral attenuation of 200 HU, a concentration of 13-15 mg iodine per milliliter (mg I/mL) iohexol or less than 3% wt/vol barium is routinely used in adults (13-16). At such OCM concentrations, low-kVp and low-keV images increase the intestinal luminal attenuation by up to 103% (17,18). This substantially higher attenuation of OCM creates challenges that may hinder adequate visualization of the bowel wall or adjacent structures and

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Key Pointsmentioning

confidence: 99%

Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The slope of the linear plot was 5.02 HU mM −1 , which was greater than that of the commercial CT contrast agent iohexol (3.95 HU mM −1 ). 58 Thus, Yb-MOFs-Glu shows great potential in CT imaging. We evaluate the feasibility of Yb-MOFs-Glu to visualize the gastrointestinal (GI) tract as a CT contrast agent.…”

Section: Resultsmentioning

confidence: 99%

Smart Metal–Organic Framework-Based Nanoplatforms for Imaging-Guided Precise Chemotherapy

Zhang¹,

Shang²,

Li³

et al. 2018

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Good biocompatibility, active tumor targeting, and stimulus-responsive release offer great opportunity for precise imaging-guided tumor treatment. However, the current strategies for the fabrication of smart theranostic platforms suffer from tedious synthesis processes. Here, we propose a universal and facile strategy for the fabrication of smart nanoscale metal− organic framework (NMOF)-based nanoplatforms for imagingguided precise chemotherapy. As a proof of concept, 5boronobenzene-1,3-dicarboxylic acid (BBDC), as a versatile ligand, was employed for the first time with Gd 3+ as metal nodes to prepare a smart magnetic resonance (MR) imaging-guided drug-delivery system. Specific reversible diol-borate condensation enables effortless coating of glucose on the NMOFs to improve their biocompatibility. The specific interaction between glucose and glucose-transported protein ensures active tumor-targeting ability. Moreover, the glucose layer, as a pH-responsive diol-borate gatekeeper, prevents the premature leakage of drugs. The proposed smart theranostic nanoplatform was well used in MR imaging-guided tumor-targeted precise chemotherapy. This strategy is simply extended to the design of other MOF−glucose composites for diverse applications, such as X-ray computed tomography imaging of gastrointestinal tract with Yb-MOFs-Glu. BBDC, as a functional ligand, provides a simple and universal way to fabricate smart NMOF theranostic platforms with multifunction as "three birds with one stone". The facile and universal strategy lays down a new way to develop multifunctional nanoagents for precision medicine.

show abstract

“…In clinical applications, iodinated contrast agents (e.g. Omnipaque (GE healthcare)) are the most generally administrated contrast materials [10]. Small molecule iodinated CT contrast agents suffer from drawbacks such as nephropathy, hypo and hyperthyroidism, low atomic number and electron density, short blood circulation time, and lack of targeting specificity [11].…”

Section: Introductionmentioning

confidence: 99%

Dual‐energy CT imaging of nasopharyngeal cancer cells using multifunctional gold nanoparticles

Khademi

Sarkar

Shakeri‐Zadeh

et al. 2019

IET nanobiotechnol.

View full text Add to dashboard Cite

The purpose of this study is to measure the concentration of gold nanoparticles (AuNPs) attached to folic acid through cysteamin as the linker (FA-Cys-AuNPs) and AuNPs in KB human nasopharyngeal cancer cells using dual-energy CT (DECT). In this study, nanoparticles with a size of ∼15 nm were synthesized and characterised using UV-Vis, TEM, FTIR and ICP-OES analyses. The non-toxicity of nanoparticles was confirmed by MTT assay under various concentrations (40-100 µg/ml) and incubation times (6, 12 and 24 h). To develop an algorithm for revealing different concentrations of AuNPs in cells, a corresponding physical phantom filled with 0.5 ml vials containing FA-Cys-AuNPs was used. The CT scan was performed at two energy levels (80 and 140 kVp). One feature of DECT is material decomposition, which allows separation and identification of different elements. The values obtained from the DECT algorithm were compared with values quantitatively measured by ICP-OES. Cells were also incubated with AuNPs and FA-Cys-AuNPs at different concentrations and incubation times. Subsequently, by increasing the incubation time in the presence of FA-Cys-AuNPs, in comparison with AuNPs, DECT pixels were increased. Thus, FA-Cys-AuNPs could be a suitable candidate for targeted contrast agent in DECT molecular imaging of nasopharyngeal cancer cells.

show abstract

Iopamidol as an oral contrast media for computed tomography: a taste comparison to iohexol, diatrizoate sodium, and barium sulfate

Abstract: There is no significant difference in palatability between iopamidol and iohexol, supporting the use of iopamidol as a viable alternative to iohexol as an oral contrast agent.

Cited by 10 publications

References 10 publications

Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial

Low-keV and Low-kVp CT for Positive Oral Contrast Media in Patients with Cancer: A Randomized Clinical Trial

Smart Metal–Organic Framework-Based Nanoplatforms for Imaging-Guided Precise Chemotherapy

Dual‐energy CT imaging of nasopharyngeal cancer cells using multifunctional gold nanoparticles

Contact Info

Product

Resources

About